News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Sustainability is integral to Biocon's business purpose
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
Launches collaborative centre for translational research in head and neck cancer
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
